Low and Middle Income Countries Opioid Substitution Therapy Market

Low and Middle Income Countries Opioid Substitution Therapy Market Snapshot from 2024 to 2034

The low and middle income countries opioid substitution therapy market is expected to develop at a CAGR of 7.4% during the forecast period.

The market value is projected to increase from USD 805.2 million in 2024 to USD 1,622.1 million by 2034. The low and middle income countries opioid substitution therapy market is valued at USD 750.2 million at the end of 2023.

Key Highlight

• Opioid substitution therapy (OST) is gaining prominence in low and middle-income countries, where drug choices depend on local prescription regulations and regulatory approvals.
• Evidence-based practices are becoming more widely used, which highlights how crucial opioid substitution therapy is to the efficient treatment of drug use disorders.
• The trend of OST integration into current healthcare systems guarantees a holistic approach to treating opioid addiction in low and middle income countries.

Attributes	Details
Estimated Market Size, 2024	USD 805.2 million
Expected Market Size, 2034	USD 1,622.1 million
Value CAGR (2024 to 2034)	7.4%

Key Dynamics Shaping the Low and Middle Income Countries Opioid Substitution Therapy Market Growth

Opioid substitution therapy has emerged as a crucial evidence-based approach for effectively managing opioid dependence. It is gaining increasing prominence in low and middle income countries (LMICs). The choice of drugs for this therapy varies across countries, contingent upon prescription regulations and approvals from relevant regulatory bodies.

Buprenorphine and methadone have garnered widespread acceptance as the treatment of choice, primarily attributed to their availability in diverse formulations, strengths, and brands. It's noteworthy that naloxone and naltrexone, both serving as opioid blockers, play distinct roles in the spectrum of substance use disorder management.

Naloxone, with its rapid-acting nature, is designed as an emergency intervention to reverse the effects of opioid overdose swiftly. Conversely, naltrexone assumes a different role. It is not intended for overdose situations. Instead, it is prescribed as a daily or monthly medication for addressing alcohol use disorder or opioid use disorder as part of ongoing treatment.

Naloxone functions as a critical tool for emergency scenarios, providing rapid response in overdose situations. On the other hand, naltrexone serves as a maintenance medication for the sustained treatment of substance use disorders.

The introduction of generic and over-the-counter (OTC) products is poised to enhance accessibility to appropriate treatment, contributing to a forecasted reduction in mortality rates. This development marks a significant stride toward ensuring effective and accessible solutions in the landscape of opioid dependence management.

Analysis of Historical and Future Outlooks of the Low and Middle Income Countries Opioid Substitution Therapy Market

The low and middle-income countries' opioid substitution therapy market recorded a historic CAGR of 5.1% in the last five years from 2019 to 2023.

Opioid use disorder (OUD) stands as a significant global health challenge, contributing to heightened rates of premature mortality and morbidity. Within the framework of comprehensive OUD treatment (OUDT), opioid substitution therapy has gained approval.

Opioid use disorders have a significant global impact, affecting over 16 million individuals. The prevalence of opioid use and dependency exhibits variations based on age and gender. Opioid-related deaths are more prevalent in older age groups, particularly between the ages of 40 and 50. However, heroin overdoses peak among individuals aged 20 to 30.

Attributes	Details
Low and Middle Income Countries Opioid Substitution Therapy Market Size, 2023	USD 750.2 million

The widespread prevalence of chronic pain and the concurrent issue of prescription opioid abuse have significant implications for patients, healthcare providers, and society at large.

Opioid treatment programs (OTPs) play a vital role in addressing these challenges by offering medication-assisted treatment (MAT) for individuals diagnosed with opioid use disorder (OUD). Increasing prevalence and awareness stand out as crucial factors propelling market growth in low and middle-income countries.

Insights into Lucrative Opportunities Propelling Low and Middle Income Countries Opioid Substitution Therapy Market

Companies dedicated to opioid substitution therapy are actively developing and introducing novel goods and technologies. They aim to improve accessibility to treatment and diagnostic procedures in low and middle-income countries. This trend has resulted in an increased demand for opioid substitution therapy.

The evolution of therapeutic molecules goes hand in hand with advancements in drug delivery technologies. Innovative delivery systems bring a host of advantages to the medical field. These include enhanced bioavailability, making them well-suited for the long-term treatment of chronic illnesses.

Additionally, such systems contribute to sustained maintenance of drug levels, reduced adverse effects, lower dosage requirements, improved patient compliance, minimized damage to healthy tissues, and the potential for cost reductions by developing new delivery systems for existing molecules. Currently, trending drug delivery mechanisms include implants, self-injectable, prefilled syringes, injectable pens, and others.

Over the past decade, a lot of innovation has occurred in injectable therapeutics. For instance, notable manufacturer Rusan Pharma introduced a wide range of product offerings in opioid substitution therapy, one of which is Verso (Naloxone), which is available in prefilled, injectable pen and vial forms.

The emergence of this innovative drug delivery technology and formulations presents promising business prospects for the opioid substitution therapy market in low and middle income countries.

Overview of Restrictive Factors for the Low and Middle Income Countries Opioid Substitution Therapy Market

The unmet medical needs in rural areas underscore the pressing necessity for improved healthcare access and resources, highlighting disparities that must be addressed to ensure comprehensive and equitable healthcare coverage. In rural parts, substance use patterns show higher rates of tobacco and methamphetamine use among adults, while opioid use has proliferated in towns of varying sizes.

Rural adolescents and young adults tend to exhibit elevated rates of alcohol consumption and engage in risky behaviors like binge drinking and driving under the influence more frequently than their urban counterparts. The battle against substance use in rural communities is complicated by resource limitations for prevention, treatment, and recovery.

Multiple factors contribute to this situation, such as limited access to education, financial hardships, joblessness, inadequate availability of mental health support, experiences of isolation and despair, and higher societal stigma around mental health and substance use issues.

 Country-wise insights

Countries	CAGR from 2024 to 2034
Brazil	3.0%
China	8.4%
India	4.1%
Malaysia	13.6%
Georgia	14.3%

Brazil's Strong Market Presence Set to Continue in 2024

Brazil dominated the low and middle-income market as of 2023. With the anticipation of sustaining this momentum, Brazil is expected to demonstrate persistent high growth throughout the forecast period.

Over the past four decades, Brazil has witnessed a steady rise in urban violence and crime, a trend persisting despite positive strides in the nation's social and economic conditions. This surge is closely connected to the escalating domestic drug consumption, prompting significant shifts in the structure, profile, and modus operandi of organized crime groups. The intertwining issues of violence and criminality find a nexus in the operations of organized crime groups engaged in arms and drug trafficking.

Brazil, currently hosting the world's fourth-leading incarcerated population, underscores the urgency for alternative approaches to address the complex challenges of violence and crime, especially in the context of drug consumption. Efforts to navigate these issues require a comprehensive strategy that considers the interconnected factors contributing to the intricate landscape of crime and violence in the country.

India to Offer the Next-door Opportunity for Market Players

In 2023, India held dominant revenue in the low and middle-income market, contributing around USD 87.25 million.

About 2.1% of India's population is grappling with opioid use, encompassing substances like opium and its derivatives such as poppy husk, heroin (or its impure forms like smack or brown sugar), and various pharmaceutical opioids. Nationally, heroin emerges as a widespread opioid (1.14%), followed by pharmaceutical opioids (0.96%) and opium (0.52%).

Notably, Nagaland, Arunachal Pradesh, Manipur, Sikkim, and Mizoram exhibit the highest prevalence of opioid use among the general population, surpassing 10%. The growing concern surrounding opioid consumption in India necessitates targeted interventions and public health initiatives to address the escalating trend.

Georgia is an Emerging Market for Low and Middle Income Countries Opioid Substitution Therapy

Georgia's healthcare system benefits significantly from its access to healthcare supplies and assistance provided by established European countries. This collaboration fosters the exchange of medical resources, expertise, and support, enhancing Georgia's ability to address healthcare challenges effectively.

This interconnected network of support reflects a commitment to regional health cooperation and underscores the importance of collective efforts in promoting the well-being of populations across borders.

Category-wise Insights

Insight into Drug Class Stimulating Growth of Low and Middle Income Countries Opioid Substitution Therapy Market

Drug Class	CAGR from 2024 to 2034
Opioid Antagonists	9.4%
Opioid Agonists and Partial Agonists	6.6%

The market value of opioid agonists and partial agonists in low and middle-income countries for opioid substitution therapy is USD 588.5 million, representing a sizable 73.6% market share in 2023. The credibility of the drug's mode of action plays a pivotal role. Given its comparatively lower efficacy, buprenorphine is widely suitable for individuals with mild to moderate dependence. In contrast, methadone is applicable across all levels of support.

Overview of Leading Indication in the Low and Middle Income Countries Opioid Substitution Therapy Market

Indication	CAGR from 2024 to 2034
Pain Management	13.1%
Opioid Withdrawal/Opioid Use Disorder (OUD)	6.5%

The market value of opioid withdrawal/opioid use disorder (OUD) in low and middle-income countries for opioid substitution therapy is USD 649.2 million, representing a sizable 86.6% market share in 2023. The prevalence of opioid use disorders, along with the complex nature of withdrawal symptoms, underscores the urgency and necessity of effective interventions and treatments within the broader healthcare landscape. As a result, the demand for solutions addressing opioid withdrawal and use disorder remains high, making it a dominant component in the spectrum of pain management, alcohol de-addiction, and mental health care.

Details on Leading Distribution Channels within the Low and Middle Income Countries Opioid Substitution Therapy Market

Distribution Channel	CAGR from 2024 to 2034
Government-supported Centers/NGO’s/Tenders	6.3%
Institutional Sales	10.2%

The government-supported centers/NGOs/tenders have a considerable presence in the low and middle-income countries' opioid substitution therapy market, accounting for 80.5% of end users in 2023.

The elevated significance of government-supported centers/NGOs/tenders in claiming the highest share stems from their crucial role in extending treatment accessibility at reduced costs. Additionally, entities funded through these channels often can provide treatment at no cost, further emphasizing their central role in ensuring widespread and affordable healthcare options.

Competitive Landscape

Market players commit resources to advance research and development, aiming to integrate innovative features, technologies, and improvements into their opioid substitution therapy. Furthermore, industry players strategically emphasize expanding their influence in key geographic regions.

This strategic expansion entails initiatives such as establishing new distribution channels, fostering partnerships with local distributors, or setting up subsidiaries in strategically advantageous locations for the effective distribution and accessibility of opioid substitution therapy solutions.

• On May 22, 2023, Indivior PLC recently disclosed that the FDA has given its approval for OPVEE (nalmefene) nasal spray, authorizing its use in emergencies for the treatment of known or suspected opioid overdose.
• On March 2, 2023, Indivior PLC acquired Opiant Pharmaceuticals, Inc. (Opiant). This strategic development enhances Indivior's addiction treatment and scientific portfolio by integrating Opiant's late-stage assets, with a notable focus on OPNT003.

Report Scope as per Low and Middle Income Countries Opioid Substitution Therapy Industry Analysis

Attribute	Details
Forecast Period	2024 to 2034
Historical Data Available for	2018 to 2023
Market Analysis	USD million for Value
Key Regions Covered	Latin America, China, South Asia and Pacific, Europe, Arica, Central Asia
Key Countries Covered	Brazil, Peru, China, India, Vietnam, Afghanistan, Bangladesh, Cambodia, Myanmar, Nepal, Pakistan, Malaysia, Thailand, Ukraine, Georgia, Armenia, Kyrgyzstan, Kazakhstan, Tajikistan, South Africa, Nigeria, Egypt, Tanzania, Ghana, Kenya, Mozambique, Senegal, Uganda, Côte d'Ivoire (Ivory Coast), and the Rest of the low and middle income countries
Key Market Segments Covered	Drug Class, Indication, Distribution Channel, and Region
Key Companies Profiled	Indivior Inc.; Alkermes, Inc; Mundipharma GmbH; Viatris Inc; Intas Pharmaceuticals; Camurus; Emergent BioSolutions Inc.; Hikma Pharmaceuticals; Pfizer Inc.; Par Pharmaceutical; Mallinckrodt Pharmaceuticals; Teva Pharmaceutical Industries Ltd.; Purdue Pharma LP; The Bristol-Myers Squibb Company; Rusan Pharma Ltd; Johnson & Johnson (Janssen Pharmaceuticals, Inc.); Takeda Pharmaceutical Company Limited; Steris Healthcare Pvt Ltd; RINQUE PHARMA (CRISTALIA); Walter Healthcare; Somerset Pharma, LLC.; Livealth; Taj Pharmaceuticals; Wellona Pharma; USWM; Sterinova; L. MOLTENI & C. DEI F.LLI ALITTI; Braeburn Inc.; Boehringer Ingelheim International GmbH; Dr. Reddy's Laboratory; Knight Therapeutics Inc.; Titan Pharmaceuticals, Inc.; Collegium Pharmaceutical; Atlantic Biologicals Corp.; Vistapharm, Inc.; JAMP PHARMA; Orexo AB; Advanced Pharmaceutical Technology, Inc.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

Key Segments Covered in Low and Middle Income Countries Opioid Substitution Therapy Market Research

By Drug Class:

• Opioid Antagonists
  • Naloxone
  • Naltrexone
• Opioid Agonists and Partial Agonists
  • Methadone
  • Buprenorphine

By Indication:

• Pain Management
• Opioid Withdrawal/Opioid Use Disorder (OUD)
• Alcohol De-addiction
• Depression

By Distribution Channel:

• Government-supported Centers/NGO’s/Tenders
• Institutional Sales
  • Hospitals
    • Public
    • Private
  • Psychiatric clinics
    • Public
    • Private
• Retail Sales
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Online Sales
  • Drug Stores

By Region:

• Latin America
• China
• South Asia and Pacific
• Europe
• Central Asia
• Africa

Frequently Asked Questions

How Big Is the Low and Middle Income Countries Opioid Substitution Therapy Market in 2023?

The market is currently valued at around USD 750.2 million in 2023.

What is the Low and Middle Income Countries Opioid Substitution Therapy Market Projected Value for 2034?

The market is set to reach a valuation of around USD 1,622.1 million by the end of 2034.

Which Drug Class Segment Contributes More to the Market?

The opioid and partial agonists segment, within the drug class segment, held a 73.6% market share in 2023.

What was the Last five years’ CAGR for the Market?

Demand for opioid substitution therapy in low and middle income countries increased at a 5.1% CAGR from 2019 to 2023.

What is the Estimated Value for Low and Middle Income Countries Opioid Substitution Therapy Market in 2024?

The estimated market value for 2024 is around USD 805.2 million.

What is the Growth Outlook of the Brazil’s Market?

Brazil accounts for around 13.8% share of the market in 2023.

What is the Growth Outlook of India’s Market?

India holds about 11.6% market share in the market in 2023.

What is the Outlook for the Georgia Market?

Georgia accounted for a market value share of around 1.9% in 2023.